What DSV’s Luxembourg–Indianapolis Pharma Air Route Reveals About the New Tariff Era
Peacock Tariff Consulting · June 2026
On 9 June 2026, DSV did something that, on its face, looks like a routine logistics announcement: the world’s largest freight forwarder opened a dedicated pharmaceutical air corridor between Luxembourg and Indianapolis. A new lane, a new hub, a press release full of the usual language about visibility, reliability and patient outcomes. Read in isolation, it is a story about cold boxes and flight schedules. Read against the backdrop of the most aggressive shift in U.S. pharmaceutical trade policy in a generation, it is something more revealing: a glimpse of how supply chains are quietly rewiring themselves around tariffs, and how logistics infrastructure is becoming a strategic instrument rather than a back-office cost.
This piece looks at what DSV actually launched, why it chose these two cities, and – most importantly for anyone tracking trade policy – how the move fits into a landscape now defined by Section 232 pharmaceutical tariffs, most-favored-nation pricing deals, and a scramble to bring drug manufacturing onto American soil.
What DSV actually launched
The new service connects Luxembourg Airport (LUX) with Indianapolis International Airport (IND) as a dedicated pharmaceutical lane. DSV has branded the operation “Indy Wings,” and positioned it as the latest expansion of its Air ThermoDirect healthcare network – the company’s temperature-controlled air-freight product built specifically for time- and temperature-sensitive medicines.
The core promise of Air ThermoDirect is deceptively simple. Most temperature-controlled pharma shipments today rely on so-called active containers: powered, refrigerated units that maintain their own internal climate, plus a tail of passive packaging, gel packs and contingency handling. They work, but they are expensive to lease and reposition, heavy, carbon-intensive, and operationally complex. DSV’s pitch is to minimize the time a shipment spends in uncontrolled environments – on tarmacs, in warehouses, between handoffs – and to remove the complexity of active containers wherever possible. The result, the company says, is a cold chain that is more predictable, more scalable, and lower in cost, emissions and operational uncertainty across critical lanes.
The executives framing the launch were explicit about its place in a larger network rather than a one-off route. Kenneth Källström, DSV’s executive vice president and global head of healthcare, said the Indianapolis operations would “play a pivotal role in the global Air ThermoDirect healthcare network, enhancing end-to-end visibility and control across pharma manufacturing regions in the US, Europe, the Americas, and APAC,” adding that strengthening these connections would help ensure “life-saving therapies move with greater speed, reliability, and integrity.”
Stephanie Penarete, vice president of Air Product Americas at DSV, tied the launch directly to a philosophy of accountability over the most fragile parts of the journey. “Indy Wings reflects our strategy to bring the critical points of the supply chain under full accountability, ensuring reliability, integrity and performance where it matters most,” she said. “With Indy Wings, we continue linking key pharmaceutical hubs with greater precision, resilience and excellence.”
“Indy Wings reflects our strategy to bring the critical points of the supply chain under full accountability – ensuring reliability, integrity and performance where it matters most.”
Notably, DSV has not publicly detailed flight frequency, aircraft type, or the carrier providing lift on the lane, and those operational specifics will matter a great deal for shippers evaluating the service. What the company has communicated is intent: a repeatable, scheduled, pharma-grade connection between a European gateway and a fast-growing American life-sciences cluster, run under DSV’s own quality umbrella rather than left to the vagaries of belly capacity and ad-hoc handling.
Why Luxembourg and why Indianapolis
Neither endpoint is an accident. Luxembourg punches far above its size in air cargo, anchored by Cargolux and a dense cluster of forwarders and pharma handlers that have invested heavily in good-distribution-practice (GDP) certified facilities. For European pharmaceutical exporters – and Europe is the dominant source of medicines flowing into the United States – Luxembourg functions as a consolidation gateway with the cold-storage infrastructure and customs throughput to move high-value, temperature-sensitive freight reliably.
Indianapolis is the more telling choice. The city has spent the past decade turning itself into one of the United States’ fastest-growing life-sciences and healthcare-logistics hubs. Central Indiana’s concentration in pharmaceutical manufacturing runs at roughly seven times the national average, anchored by Eli Lilly, which is headquartered in the city and has committed more than $13 billion to build the Lilly Medicine Foundry in nearby Lebanon, Indiana. Indianapolis International ranks among the top ten cargo airports in the United States and sits alongside the second-largest FedEx air hub in the world, giving it the runway capacity, ramp access and onward-distribution reach that pharma freight demands.
DSV is also not the first mover here, which underscores the point. DHL Global Forwarding opened a pharma-focused logistics facility at Indianapolis International with direct ramp access and a transatlantic freighter link to Liège; DB Schenker – now part of DSV – has operated cold-room and controlled-room-temperature space in Indianapolis since 2006, precisely because of its proximity to Eli Lilly; and rivals such as Geodis have been adding pharma cross-dock capacity at U.S. gateways. In other words, the smart money in pharma logistics has been converging on Indianapolis for years. DSV’s move is less about discovering the hub than about cementing a premium, branded, transatlantic position in it.
The tariff backdrop that changes everything
Here is where a cold-chain story becomes a trade-policy story. The transatlantic pharma lane DSV is reinforcing is precisely the lane now under the heaviest tariff pressure in modern memory.
On 2 April 2026, the White House issued a proclamation invoking Section 232 of the Trade Expansion Act of 1962 – the national-security statute – to impose tariffs on patented pharmaceutical products and active pharmaceutical ingredients (APIs). The structure is deliberately punitive at the top and steeply tiered below it. The default rate on covered patented drugs is 100%. Imports from the European Union, Japan, South Korea, and Switzerland and Liechtenstein are capped at a far lower 15%, reflecting framework trade arrangements with those partners. And companies that strike both most-favored-nation (MFN) pricing agreements with the U.S. Department of Health and Human Services and onshoring commitments with the Commerce Department can secure a 0% rate through 20 January 2029.
The timeline is imminent. The tiered rates take effect on 31 July 2026 for companies named in the proclamation’s annex, and on 29 September 2026 for everyone else. Generic drugs – the high-volume, low-margin backbone of the U.S. pharmacy – largely get a pass, concentrating the burden on the patented, innovative, often biologic therapies that also happen to be the most temperature-sensitive and the most valuable per kilogram.
The exposure is enormous because the trade is enormous. In 2023 the United States imported roughly $203 billion in pharmaceutical products, and about 73% of that came from Europe – led by Ireland, Germany and Switzerland. A 15% wall on EU-origin patented medicines, with a 100% cliff looming behind it for anyone outside the favored tiers, is not a rounding error. It is a structural tax on exactly the freight that moves through gateways like Luxembourg toward hubs like Indianapolis.
A 15% wall on EU-origin patented medicines – with a 100% cliff behind it for anyone outside the favored tiers – is a structural tax on exactly the freight DSV’s new lane is built to carry.
What today’s applied rate actually looks like
It is worth separating the headline from the math, because the two diverge in instructive ways. Modeling a finished medicament (HS heading 3004) imported from a Luxembourg origin as of mid-June 2026 produces an applied U.S. duty of roughly 10% – not from the Section 232 pharma measure, which has not yet taken effect, but from a Section 122 balance-of-payments surcharge. That surcharge became the operative regime after the Supreme Court struck down the administration’s IEEPA-based tariffs on 20 February 2026, forcing a pivot to other statutory tools. An EU “tariff floor” framework is in force across all 27 member states, and for pharmaceuticals its effect is moderated by the non-patented share of a given product.
The practical lesson for shippers is that pharma tariff exposure in 2026 is layered and legally contingent, not a single number. There is the surcharge that already applies; the Section 232 pharma tariff scheduled to layer in from late July; the patented-versus-generic distinction that determines whether a product is even in scope; and the company-specific MFN and onshoring deals that can collapse the rate to zero. For a consulting practice advising drug makers, the spread between a 0% negotiated rate and a 100% default is the entire ballgame – and it turns logistics design into a variable that interacts directly with duty liability.
A note on sourcing: applied-rate figures here are drawn from Global Trade Alert’s U.S. tariff model, which covers measures from 20 January 2025 onward. As with any fast-moving policy area, company-specific outcomes depend on annex listings, deal status and product classification.
Reading the route as a tariff hedge
Why would a forwarder pour resources into reinforcing a transatlantic pharma lane at the exact moment tariffs threaten to throttle transatlantic pharma trade? Because tariffs do not eliminate the trade – they reprice and reshape it, and reshaping is where logistics earns its margin.
First, value density rises. When a 15% (or worse) duty is levied on the customs value of a shipment, the economic case for protecting that shipment from spoilage, delay and rework grows in lockstep. A temperature excursion that ruins a consignment now destroys not only the product but the duty already paid or owed on it. Reliability becomes a tariff-mitigation tool.
Second, onshoring multiplies internal lanes. The clearest path to the 0% tier runs through onshoring agreements with the Commerce Department. As companies like Eli Lilly pour tens of billions into U.S. manufacturing capacity, they create vast new internal and inbound flows – APIs, intermediates, equipment, comparator drugs for trials, and finished goods moving between European and American sites within the same corporate network. Indianapolis sits at the center of that build-out. A forwarder with a dedicated, branded position there is selling shovels in a gold rush, regardless of which way any single finished-goods tariff cuts.
Third, complexity is the product. Tariff tiers that hinge on patent status, country of origin, annex listings and bilateral deals turn customs classification and trade compliance into a high-stakes discipline. Forwarders that can pair physical cold-chain control with classification accuracy, bonded handling, and origin documentation become far stickier partners. “Full accountability” over the critical points of the chain, in Penarete’s phrase, reads differently when one of those critical points is a tariff line.
A fourth, quieter dynamic deserves attention: clinical and pre-commercial logistics are largely indifferent to finished-goods tariffs, yet they move on the same lanes. Investigational medicinal products, comparator drugs, biological samples and trial kits shuttle constantly between European and U.S. research sites, and they are among the most temperature-sensitive and time-critical freight in existence. As pharmaceutical companies expand U.S. footprints to chase the onshoring incentive, the volume of this research-stage traffic between European hubs and American clusters like Indianapolis tends to grow regardless of where finished-product duties land. A dedicated, quality-assured corridor is well suited to capture exactly this resilient, high-margin flow – one that sits largely outside the tariff crosshairs while still benefiting from the same infrastructure built to serve commercial shipments.
None of this means DSV designed Indy Wings as an explicit tariff play; the public messaging is squarely about temperature integrity and emissions. But strategy and circumstance rhyme. A dedicated Luxembourg–Indianapolis pharma corridor is exactly the kind of asset that pays off whether trade flows shift toward more finished-goods imports under negotiated low rates, or toward more intra-company movement as manufacturing reshores. It is, in effect, a hedge dressed as a cold box.
The cold-chain economics that make the lane bankable
Strip away the policy overlay and the underlying business still has to stand on its own – and it does. The economic waste in pharmaceutical cold chains is staggering. Industry estimates, including widely cited figures from IQVIA, put annual losses from temperature excursions in the range of $20 billion to $35 billion in spoiled or wasted product. Roughly one in eight pharmaceutical shipments still experiences a temperature excursion at some point in its journey, and the World Health Organization has estimated that nearly a quarter of vaccines are degraded by the time they reach their destination.
Crucially, most of that loss is not caused by equipment failure. It stems from human error and a lack of visibility – the handoffs, dwell times and uncontrolled gaps that DSV’s Air ThermoDirect model is explicitly designed to compress. That is the wedge: if you can shrink the time product spends exposed and reduce reliance on failure-prone active units, you attack the largest, most addressable source of loss in the system.
The market tailwind is equally clear. The global cold-chain logistics market is projected to approach $505 billion by 2032, propelled by the growing share of biologics, cell and gene therapies, and precision medicines – products that are both extraordinarily valuable and extraordinarily fragile. Layer rising tariff values on top of rising product values, and the willingness to pay for guaranteed integrity only increases. A lane that credibly reduces excursion risk on high-value transatlantic pharma is bankable on fundamentals alone, before a single tariff argument is made.
DSV’s scale and the competitive field
Context on the company sharpens the significance of the move. In April 2025, DSV completed its roughly €14.3 billion acquisition of Schenker, a deal that doubled the Danish group’s size and lifted combined revenue to around €41.6 billion, with some 160,000 employees across about 90 countries. The acquisition made DSV the largest global freight forwarder by turnover – and, just as relevantly for this story, it folded Schenker’s long-standing Indianapolis pharma footprint into the DSV network. Indy Wings is partly the product of that integration: a chance to rationalize and rebrand inherited capacity into a flagship, premium healthcare lane.
DSV is moving into contested territory. DHL has a mature pharma operation at Indianapolis with its own transatlantic freighter connectivity; Kuehne+Nagel, Geodis and the integrators all court the same life-sciences shippers; and airlines from Lufthansa Cargo to Qatar Airways Cargo are racking up CEIV Pharma certifications and rolling out smarter temperature solutions to capture the same high-margin freight. Differentiation increasingly comes not from having a cold room, but from owning the end-to-end choreography – and, in the current environment, from being able to speak fluently about duty exposure as well as dew point.
The unresolved questions
Several uncertainties temper the optimism. The most obvious is policy volatility. The Section 232 pharma regime has already been reshaped once by litigation – the Supreme Court’s February 2026 rejection of the IEEPA tariffs forced the pivot to Section 122 – and further legal challenges, deal renegotiations, and annex revisions are likely. A lane optimized for one tariff configuration could face a materially different one within a quarter. Trade-dependent infrastructure investments are being made against a moving target.
There is also a demand-direction risk. If onshoring succeeds at scale, the long-run trajectory for finished-drug imports into the United States is downward, at least for the patented products in tariff scope. DSV’s bet implicitly assumes that intra-network flows, clinical-trial logistics, API movement and the sheer stickiness of European manufacturing will more than offset any decline in straightforward finished-goods imports. That is a reasonable assumption – manufacturing relocation takes years and rarely fully displaces existing sites – but it is an assumption nonetheless.
Operational opacity is a third caveat. Without disclosed frequency, capacity and carrier arrangements, it is hard to gauge how much real lift Indy Wings adds versus how much it formalizes flows DSV already handled. And the broader air-cargo market is tight: DSV itself has flagged limited wide-body freighter capacity, which constrains how quickly any premium pharma lane can scale when demand spikes.
What to watch – and what it means
For trade-policy watchers and the companies they advise, DSV’s Luxembourg–Indianapolis lane is worth treating as a signal rather than a headline. It says that sophisticated logistics players expect transatlantic pharma trade to remain large and lucrative even under tariffs – reshaped, repriced, and more compliance-intensive, but not extinguished. It says that the value of supply-chain control rises precisely when duty exposure rises. And it says that American life-sciences clusters like Indianapolis are becoming the gravitational centers around which both manufacturing and logistics reorganize, accelerated by the 0% onshoring incentive baked into the tariff structure.
The practical watch list is short. Track whether the 31 July and 29 September 2026 Section 232 effective dates hold, and how many companies land in the 0% MFN-plus-onshoring tier versus the 15% and 100% tiers. Watch the litigation that could again redraw the statutory basis for the tariffs. Monitor whether DSV and its rivals expand, contract or re-route their U.S. pharma gateways as those rates settle. And, for shippers, treat logistics design and tariff strategy as a single problem rather than two – because in 2026, the cost of moving a medicine and the cost of importing it have become inseparable.
The takeaway: a single new air route is rarely worth a thousand words. This one is, because it sits at the precise intersection of cold-chain economics and a tariff regime that is rewriting the map of global pharmaceutical trade. DSV is building physical infrastructure for a policy environment that is still being written – and betting, plausibly, that whichever way the rules fall, the company that controls the critical points of the chain will be the one that wins.